Translation

Prowess in the synthesis and delivery of therapeutics and diagnostics is a hallmark of the Chemistry of Life Processes Institute (CLP) that reflects its origins in the discovery of Lyrica® by Dr. Richard Silverman. CLP is committed to harnessing the power of transdisciplinary research among fields such as life sciences, physical sciences, engineering, and medicine to translate research into the marketplace where it can exert a profound beneficial impact on human health. CLP transdisciplinary scientists understand that interactions with the business world are critical if a new discovery is going to make it out of the lab and into the world where it can help people.

Companies Founded by CLP Faculty

Founder: Andrew Mazar
Co-Founders: Francis Giles, Andrey Ugolkov

Founder: William Klein
Co-Founder: Grant Krafft

Founder: Vadim Backman
Co-Founders: Andrew Cittadine, Michael Goldberg, Hemant K. Roy

Founder: Lonnie Shea
Co-Founder: Stephen Miller

Founder: Colby Thaxton
Co-Founder: Chad Mirkin

Founder: Neil Kelleher
Co-Founder: Phil Compton

Founder: Richard Silverman
Co-Founder: Pfizer

Founder: Neil Kelleher
Co-Founder: Regan Thomson

Founder: Andrew Mazar
Co-Founders: Thomas O’Halloran, Andrey Ugolkov

Founder: Vadim Backman
Co-Founders: Hemant K. Roy, Hariharan Subramanian

Founder: Phillip Messersmith

Founder: Thomas Meade

Founders: Cheng Sun, Hao Zheng

Founder: Olga Volpert
Co-Founder: Jack Henkin

Founder: Thomas Meade

Founder: Vadim Backman

Founder: Thomas O’Halloran
Co-Founder: Chandler Robinson

Founder: Karl Scheidt
Co-Founder: Raymond Bergan

Founder: Richard Silverman
Co-Founders: Dmitri Krainc

Founder: Jack Henkin
Co-Founders: Andrew Mazar, Olga Volpert

Founder: Guillermo Ameer
Co-Founders: Melina R. Kibbe, Antonio Webb

Founder: Thomas O’Halloran
Co-Founder: Robert Schotzinger

Northwestern Partners in Entrepreneurship

Innovation and New Ventures Office (INVO)

INVO catalyzes the translation of Northwestern innovations to benefit the public and promote economic growth. In order to maximize that outcome, Northwestern follows important principles when licensing university technology. 

NewCures Fund

NewCures is a Northwestern initiative that focuses on accelerating biomedical research from early discovery stages to more advanced clinical stages for the benefit of the patients. The NewCures Fund aligns with existing resources to propel promising therapies towards commercialization. 

Entrepreneur-in-Residence Program

Entrepreneurs-in-Residence (EIR) advise and assist faculty and students who are launching startups and commercializing IP. They are a resource for developing business concepts, making contacts with the market, connecting to investors, and forming organizational frameworks. 

Chicago Biomedical Consortium (CBC)

The CBC stimulates collaboration among researchers at Northwestern University, The University of Chicago, the University of Illinois at Chicago, and others to accelerate discovery that transforms biomedical research and improves the health of humankind.

Basic Science Discoveries Translated into Healthcare

Unlocking Cures to Orphan Diseases

Unlocking Cures to Orphan Diseases

Professor Richard Silverman (Chemistry and Molecular Biology) is not content to rest on his laurels following his extraordinary discovery of pregabalin (Lyrica®). Instead, he has used the translational resources of the Chemistry of Life Processes Institute to develop...

Early Detection Saves Eyes

Early Detection Saves Eyes

Nearly 40 million Americans are at risk for vision loss or blindness due to diabetes and age-related macular degeneration. Often, these diseases are diagnosed and treated much too late, after irreversible vision loss has started to occur. Hao F. Zhang (Biomedical...